Advertisement
Home Tags Cancer: Leukemia

Tag: Cancer: Leukemia

After hematopoietic stem cell transplantation for acute leukemia

Leukemia Patients Who Survive Severe GVHD Often Fare Worse

0
Those who develop severe acute graft-versus-host after stem cell transplant have higher mortality
Outcomes of treatment with third-generation CAR T-cell therapy in CD19-positive B-cell malignancy are associated with patients' immune status

Immune Status Tied to Outcomes in Third-Gen CAR T-Cell Therapy

0
In leukemia/lymphoma, after treatment CD19-targeting chimeric antigen receptor T-cell therapy
The U.S. Food and Drug Administration on Wednesday approved the first gene therapy -- Kymriah (tisagenlecleucel) -- in the United States

FDA Approves First Gene Therapy in the United States

0
Kymriah approved for patients up to 25 years of age with refractory or relapsed B-cell precursor ALL
The U.S. Food and Drug Administration on Thursday approved Besponsa (inotuzumab ozogamicin) to treat B-cell acute lymphoblastic leukemia.

FDA Approves New Treatment for Acute Lymphoblastic Leukemia

0
For patients with relapsed or refractory B-cell ALL who have received one or two prior treatments

FDA Approves New Treatment for Acute Myeloid Leukemia

0
Vyxeos combines two previously approved drugs -- daunorubicin and cytarabine

FDA Approves Idhifa for Some With Acute Myeloid Leukemia

0
For adults with relapsed or refractory AML who have an IDH2 genetic mutation

FDA Approves Imbruvica to Treat Chronic Graft Versus Host Disease

0
Drug sanctioned for patients with cGVHD who do not respond to other forms of therapy
The potential first gene therapy in the United States is being reviewed by a U.S. Food and Drug Administration expert panel.

Potential First U.S. Gene Therapy Now Under FDA Review

0
Tisagenlecleucel could be a one-time treatment for children and young adults with advanced leukemia
For patients with acute myeloid leukemia and a FLT3 mutation

Longer Survival for Midostaurin + Chemotherapy in AML With FLT3

0
Prolonged overall, event-free survival for patients with acute myeloid leukemia, FLT3 mutation
Rydapt (midostaurin) has been approved by the U.S. Food and Drug Administration

FDA Approves Kinase Inhibitor for Treatment of AML

0
Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults